NCT05504681 Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
| NCT ID | NCT05504681 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baptist Health South Florida |
| Condition | Neurocognitive Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-11-30 |
| Primary Completion | 2026-04 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.
Eligibility Criteria
Inclusion Criteria: 1. All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and/or antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI) 2. Life expectancy ≥ 6 months 3. Willingness to participate in ongoing registration study Exclusion Criteria: 1. Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.) 2. Pediatric patients (\<18 years old), pregnant women, and prisoners.